Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
View Study [5]"Efficacy and safety of CagriSema in type 2 diabetes" Frias JP et al., 2023 Finding: In people with type 2 diabetes, CagriSema achieved 15.6% weight loss versus 5.1% with semaglutide alone over 32 weeks, with comparable HbA1c reductions and good tolerability
They observed slightly quicker arousal than usual in bed and were more receptive to sex
International Journal of Molecular Sciences, 24(8), 4567-4582.
Yamagishi, GIP as a potential therapeutic target for atherosclerotic cardiovascular disease: a systematic review
It covers more pathways than CagriSema (which is missing GIP) but fewer than cag + retatrutide (which adds glucagon)
US$ 20.24
US$ 25.42
US$ 27.64
US$ 28.22
